Ropes & Gray represented CAMP4 Therapeutics in an oversubscribed private placement to raise up to $100 million, including $50 million in upfront gross proceeds and an additional $50 million subject to achieving pre-specified milestones. The transaction was announced in a press release on Sept. 10.
CAMP4 is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases.
The team was led by capital markets partner Tom Danielski.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.